# Neurocrine Biosciences clinical trials: 87 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 87 trials with Neurocrine Biosciences as lead sponsor, 16 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Neurocrine Biosciences: 87 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/neurocrine-biosciences

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 87
- Recruiting or not yet: 16
- Read on: November 19, 2026

## Trials

The 25 newest of 87, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07934303 | Study of NBIB-223 Gene Therapy in Friedreich's Ataxia (FACET) | Neurocrine Biosciences | Phase 1 | Not yet recruiting | Friedreich's Ataxia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07934303) |
| September 30, 2026 | NCT07850739 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH) | Neurocrine Biosciences | Phase 2 | Not yet recruiting | Congenital Adrenal Hyperplasia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850739) |
| September 22, 2026 | NCT07832383 | Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor | Neurocrine Biosciences | Phase 2 | Not yet recruiting | Alzheimer's Disease | 135 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832383) |
| January 26, 2026 | NCT07365462 | Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | Neurocrine Biosciences | Phase 2 | Recruiting | Tardive Dyskinesia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365462) |
| December 17, 2025 | NCT07288333 | Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia | Neurocrine Biosciences | Phase 2 | Recruiting | Schizophrenia | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288333) |
| December 17, 2025 | NCT07288320 | An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania | Neurocrine Biosciences | Phase 2 | Recruiting | Bipolar I Disorder, Mania | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07288320) |
| November 13, 2025 | NCT07227818 | Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 560 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07227818) |
| September 29, 2025 | NCT07196501 | A Study to Evaluate the Maintenance Effect of Osavampator as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07196501) |
| August 11, 2025 | NCT07114874 | NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 600 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07114874) |
| August 5, 2025 | NCT07105111 | A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While... | Neurocrine Biosciences | Phase 4 | Recruiting | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105111) |
| August 5, 2025 | NCT07105098 | NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105098) |
| May 11, 2025 | NCT06966401 | Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 850 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06966401) |
| May 8, 2025 | NCT06963034 | NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia | Neurocrine Biosciences | Phase 3 | Recruiting | Schizophrenia | 284 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963034) |
| May 8, 2025 | NCT06963021 | NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06963021) |
| April 4, 2025 | NCT06911112 | NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major... | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06911112) |
| January 22, 2025 | NCT06786624 | Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Neurocrine Biosciences | Phase 3 | Recruiting | Major Depressive Disorder | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06786624) |
| March 15, 2024 | NCT06312189 | Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada | Neurocrine Biosciences | Phase 3 | Enrolling by invitation | Chorea, Huntington | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06312189) |
| February 20, 2024 | NCT06267846 | A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder | Neurocrine Biosciences | Phase 2 | Completed | Major Depressive Disorder | 73 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06267846) |
| May 16, 2023 | NCT05859698 | Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia | Neurocrine Biosciences | Phase 4 | Completed | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Tardive Dyskinesia | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05859698) |
| December 16, 2022 | NCT05654870 | Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia | Neurocrine Biosciences | Phase 3 | Terminated | Schizophrenia | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05654870) |
| September 19, 2022 | NCT05545111 | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia | Neurocrine Biosciences | Phase 2 | Completed | Schizophrenia | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05545111) |
| August 9, 2022 | NCT05493293 | Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset... | Neurocrine Biosciences | Phase 2 | Terminated | Focal Onset Seizure, Focal Onset Epilepsy | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05493293) |
| March 31, 2022 | NCT05301894 | Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep | Neurocrine Biosciences | Phase 2 | Terminated | Epileptic Encephalopathy, Continuous Spike and Wave During Sleep | 19 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05301894) |
| February 7, 2022 | NCT05226780 | Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE | Neurocrine Biosciences | Phase 2 | Terminated | SCN8A Developmental and Epileptic Encephalopathy Syndrome | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05226780) |
| January 25, 2022 | NCT05206513 | Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy | Neurocrine Biosciences | Phase 3 | Completed | Dyskinesia, Cerebral Palsy | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05206513) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 22 |
| Phase 2 | 36 |
| Phase 3 | 22 |
| Phase 4 | 4 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 54 |
| Recruiting | 13 |
| Terminated | 11 |
| Not yet recruiting | 3 |
| Withdrawn | 2 |
| Active not recruiting | 2 |
| Enrolling by invitation | 1 |
| Unknown | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Schizophrenia | 15 |
| Tardive Dyskinesia | 13 |
| Depressive Disorder, Major | 10 |
| Tourette Syndrome | 8 |
| Depression | 8 |
| Parkinson Disease | 6 |
| Adrenal Hyperplasia, Congenital | 6 |
| Epilepsy | 5 |
| Movement Disorders | 3 |
| Huntington Disease | 3 |
| Neurodegenerative Diseases | 2 |
| Congenital adrenal hyperplasia due to 21 hydroxylase deficiency | 2 |
| Chorea | 2 |
| Psychotic Disorders | 2 |
| Bipolar Disorder | 2 |
| Seizures | 2 |
| Sleep Initiation and Maintenance Disorders | 2 |
| Friedreich Ataxia | 2 |
| Central Nervous System Neoplasms | 1 |
| Brain Neoplasms | 1 |
| Glioblastoma | 1 |
| Gliosarcoma | 1 |
| Basal Ganglia Diseases | 1 |
| Brain Diseases | 1 |
| Central Nervous System Diseases | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Blueprint printers in the United States](https://specstream.ai/data/businesses/blueprint-printers/united-states)
- [Plastic and reconstructive surgery practices in the United States](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/united-states)
- [Doner kebab restaurants in the United States](https://specstream.ai/data/businesses/doner-kebab-restaurants/united-states)
- [Stone suppliers in the United States](https://specstream.ai/data/businesses/stone-suppliers/united-states)
- [Hawaiian restaurants in the United States](https://specstream.ai/data/businesses/hawaiian-restaurants/united-states)
- [Allergy and immunology practices in the United States](https://specstream.ai/data/businesses/allergy-and-immunology-practices/united-states)
